Compare DMRC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMRC | MOLN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | 134 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 143.3M |
| IPO Year | 2008 | 2021 |
| Metric | DMRC | MOLN |
|---|---|---|
| Price | $9.48 | $3.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $8.38 |
| AVG Volume (30 Days) | ★ 276.6K | 3.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $3.41 |
| 52 Week High | $17.47 | $5.36 |
| Indicator | DMRC | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 45.21 |
| Support Level | $9.52 | $3.61 |
| Resistance Level | $10.31 | $3.96 |
| Average True Range (ATR) | 1.26 | 0.13 |
| MACD | -0.68 | 0.00 |
| Stochastic Oscillator | 3.78 | 33.33 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.